Fighting Dengue: Interview with Sanofi

ISSUE #64 – In late 2016, Singapore approved a dengue vaccine developed by Sanofi, Cyril Grandchamp-Desraux, Singapore Country Chair and Asia Head, General Medicines & Emerging Markets, tells us more about Sanofi’s commitment to improving health in Singapore and across Asia.

 

What are Sanofi’s main activities around the world?

Cyril Grandchamp DesrauxSanofi is a global, diversified life science company whose everyday focus is to protect and improve health. From prevention with vaccines, to self-medication products available at pharmacies, specialty care treatments, or integrated innovative solutions for wide-spread, chronic diseases like diabetes: we support patients every step of their health journey by providing innovations that empower everyone to lead a healthier life.

 

What specific fields does Sanofi focus on in Asia?

Our focus is needs-driven: we adapt to each country to ensure we are where the diseases are.

Diabetes is one of the most pressing needs in the region, with Asia accounting for approximately half of the cases in the world. In this field, we work on integrated solutions – combining device, software, medicine and professional care – to support patients and help them simply and effectively manage their diabetes.

Specialty care is another major area, with complex conditions – like rare diseases, multiple sclerosis, immune diseases – that are challenging to treat and sometimes to identify, making patients’ journey to diagnosis often long, difficult and lonely. As a response, we provide specialised transformative treatments along with diagnosis, medical education and support programmes for patients and their families, in close collaboration with health authorities, physicians, caregivers and patient communities. Another major public health threat in the region is dengue, which is now a vaccine-preventable disease, thanks to the relentless efforts of our teams.

Our focus is needs-driven: we adapt to each country to ensure we are where the diseases are.

 

What led Sanofi to work on the development of this dengue vaccine?

With increased urbanisation, population mobility, and climate change, Asia has never been more vulnerable to the spread of fast-growing diseases, including dengue. In the past five decades, we have seen a 30-fold increase in the spread of dengue, with outbreaks reaching over 128 countries. Asia alone bears 70% of the disease burden.

As a consequence, Sanofi Pasteur, our vaccines division, spent 20 years researching and developing the world’s first dengue vaccine, with – for the first time – proven efficacy against all four serotypes of dengue. Moreover, in a recommendation published in July 2016, the World Health Organization endorsed the vaccine as a significant contribution to integrated dengue prevention efforts in highly endemic countries, and to public health at large.

In Asia, our vaccine was approved for prevention in Singapore in October 2016, as well as in the Philippines, Indonesia, Thailand and Malaysia. As one of the world’s largest and long-standing vaccine producers, we aim to contribute to a world where no one suffers or dies from a vaccine-preventable disease. This vaccine testifies to our long-standing commitment to improving health and to being where patients need us.

 

 


Sanofi is a global life sciences company committed to improving access to healthcare and supporting the people we serve throughout the continuum of care. From prevention to treatment, Sanofi transforms scientific innovation into healthcare solutions, in human vaccines, rare diseases, multiple sclerosis, oncology, immunology, infectious diseases, diabetes and cardiovascular solutions and consumer healthcare. Find out more about Sanofi on the Smart Health platform.

 

Interview with Cyril Grandchamp-Desraux, Singapore Country Chair and Asia Head, General Medicines & Emerging Markets, Sanofi

Published in FOCUS Magazine — Issue #3 2017 “In the Pink of Health”

 

 

Smart Health Launched 2

exporter-simplanter-singapour-asie-2